Please assess the completion status of the following clinical trial:

Trial Title: CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.~* No more than 3 previous anti-myeloma regimens~* No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.~* Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).~Exclusion Criteria:~* Prior development of disease progression during high-dose dexamethasone containing therapy.~* Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm cubed~* Laboratory abnormalities: Platelet count less than 75,000/mm cubed~* Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL~* Laboratory abnormalities: Serum glutamic oxaloacetic transaminase (SGOT, aspartate transaminase \[AST\]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase \[ALT\])greater than 3.0 x upper limit of normal~* Laboratory abnormalities: Serum total bilirubin greater than 2.0 mg/dL~* Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.~* Known hypersensitivity to thalidomide or dexamethasone.~* Development of a desquamating rash while taking thalidomide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-5013/Dex (Type: EXPERIMENTAL): CC-5013 (lenalidomide) plus oral high-dose dexamethasone
- Placebo/Dex (Type: EXPERIMENTAL): Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).